Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?Think back to the last patient in your practice who died of mCRC: How many lines of therapy did that patient receive? Did that patient receive regorafenib at some point during his or her course of metastatic disease?
Answer: >5; Yes
The last patient in my practice who died of mCRC lived with the disease for close to 7 years after receiving more than 5 lines of therapy in the metastatic setting. It’s amazing to see how long many patients are able to live with CRC, particularly with all the different therapeutic options now available. This patient did receive regorafenib at some point during the course of the disease. In all, about 6 to 10 patients in my practice died of CRC in the past year.
Answer: 2; No
Thinking back, the last patient who died of mCRC in my practice received 2 lines of therapy. This patient was diagnosed with KRAS mutation-positive mCRC at the age of 50 years. He had a performance status of 3 and lived with the disease for about 1 year. In general, most of my patients live for at least 2 years with metastatic disease. In all, more than 10 patients in my practice died of CRC in the past year. Most of my patients received bevacizumab beyond progression, and most with KRAS wild-type disease would have received cetuximab. However, the last patient who died of mCRC in my practice did not receive regorafenib.
Answer: 4; Yes
I don’t know the exact number of patients in my practice who died of CRC in the past year. If I were to guess, I would say about 15. The last patient who died of mCRC in my practice was a 75-year-old woman with KRAS wild-type disease. She received 4 lines of therapy and lived with mCRC for 3½ years. She did receive regorafenib during the course of her mCRC.
Answer: 3; Yes
The last patient with mCRC who died in my practice in the past year received 3 lines of therapy, and regorafenib was among the therapies received. This patient lived with KRAS mutation-positive mCRC for 1 to 2 years. More than 10 patients in my practice died of CRC in the past year.
Answer: >5; Yes
In the past year, more than 10 patients died of CRC in my practice. My last patient who died of mCRC received more than 5 lines of systemic therapy, including regorafenib. She lived with KRAS-mutant mCRC for 8 years.
Answer: 5; Yes
I believe 3 to 5 patients in my practice died of mCRC in the past year. The last patient who died of mCRC received about 5 lines of therapy and lived for more than 3 years with the disease. She received regorafenib at some point in the course of her mCRC.
Answer: 3 to 4; Yes
Unfortunately, more than 10 patients in my practice died of CRC in the past year. The last patient who died received about 3 to 4 lines of therapy for metastatic disease. The fourth line of therapy was an experimental agent. I don’t remember how long my last patient lived with mCRC, but most of my patients live with the disease for 2 to 3 years. I have a couple of patients who lived with the disease for more than 3 years, but few patients in my practice live with it for 1 year or less. I believe the last patient would have received regorafenib as part of the treatment for mCRC.
Answer: ≥3; Yes
In my practice, more than 10 patients died of CRC in the past year. The last patient who died received at least 3 lines of therapy for metastatic disease. We have a robust drug development program. As such, many of my patients are able to receive up to 6 lines of therapy, depending on the availability of/eligibility for Phase I trials. My last patient who died of mCRC lived with the disease for 2 to 3 years and did receive regorafenib. |
